377 related articles for article (PubMed ID: 10188764)
1. Aprotinin: an update of its pharmacology and therapeutic use in open heart surgery and coronary artery bypass surgery.
Peters DC; Noble S
Drugs; 1999 Feb; 57(2):233-60. PubMed ID: 10188764
[TBL] [Abstract][Full Text] [Related]
2. Review and application of serine protease inhibition in coronary artery bypass graft surgery.
Engles L
Am J Health Syst Pharm; 2005 Sep; 62(18 Suppl 4):S9-14. PubMed ID: 16227196
[TBL] [Abstract][Full Text] [Related]
3. Aprotinin. A review of its pharmacology and therapeutic efficacy in reducing blood loss associated with cardiac surgery.
Davis R; Whittington R
Drugs; 1995 Jun; 49(6):954-83. PubMed ID: 7543841
[TBL] [Abstract][Full Text] [Related]
4. Drug, devices, technologies, and techniques for blood management in minimally invasive and conventional cardiothoracic surgery: a consensus statement from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011.
Menkis AH; Martin J; Cheng DC; Fitzgerald DC; Freedman JJ; Gao C; Koster A; Mackenzie GS; Murphy GJ; Spiess B; Ad N
Innovations (Phila); 2012; 7(4):229-41. PubMed ID: 23123988
[TBL] [Abstract][Full Text] [Related]
5. Tranexamic acid: a review of its use in surgery and other indications.
Dunn CJ; Goa KL
Drugs; 1999 Jun; 57(6):1005-32. PubMed ID: 10400410
[TBL] [Abstract][Full Text] [Related]
6. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
Dietrich W; Spannagl M; Boehm J; Hauner K; Braun S; Schuster T; Busley R
Anesth Analg; 2008 Nov; 107(5):1469-78. PubMed ID: 18931201
[TBL] [Abstract][Full Text] [Related]
7. Tranexamic acid and aprotinin reduce postoperative bleeding and transfusions during primary coronary revascularization.
Mongan PD; Brown RS; Thwaites BK
Anesth Analg; 1998 Aug; 87(2):258-65. PubMed ID: 9706913
[TBL] [Abstract][Full Text] [Related]
8. Aprotinin.
Robert S; Wagner BK; Boulanger M; Richer M
Ann Pharmacother; 1996 Apr; 30(4):372-80. PubMed ID: 8729892
[TBL] [Abstract][Full Text] [Related]
9. The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis.
Henry D; Carless P; Fergusson D; Laupacis A
CMAJ; 2009 Jan; 180(2):183-93. PubMed ID: 19050037
[TBL] [Abstract][Full Text] [Related]
10. Changes in coagulation patterns, blood loss and blood use after cardiopulmonary bypass: aprotinin vs tranexamic acid vs epsilon aminocaproic acid.
Menichetti A; Tritapepe L; Ruvolo G; Speziale G; Cogliati A; Di Giovanni C; Pacilli M; Criniti A
J Cardiovasc Surg (Torino); 1996 Aug; 37(4):401-7. PubMed ID: 8698787
[TBL] [Abstract][Full Text] [Related]
11. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery.
Mangano DT; Miao Y; Vuylsteke A; Tudor IC; Juneja R; Filipescu D; Hoeft A; Fontes ML; Hillel Z; Ott E; Titov T; Dietzel C; Levin J; ;
JAMA; 2007 Feb; 297(5):471-9. PubMed ID: 17284697
[TBL] [Abstract][Full Text] [Related]
12. Aprotinin decreases postoperative bleeding and number of transfusions in patients on clopidogrel undergoing coronary artery bypass graft surgery: a double-blind, placebo-controlled, randomized clinical trial.
van der Linden J; Lindvall G; Sartipy U
Circulation; 2005 Aug; 112(9 Suppl):I276-80. PubMed ID: 16159831
[TBL] [Abstract][Full Text] [Related]
13. Aprotinin reduces bleeding and blood product use in patients treated with clopidogrel before coronary artery bypass grafting.
Lindvall G; Sartipy U; van der Linden J
Ann Thorac Surg; 2005 Sep; 80(3):922-7. PubMed ID: 16122456
[TBL] [Abstract][Full Text] [Related]
14. Aprotinin vs. tranexamic acid in isolated coronary artery bypass surgery: A multicentre observational study.
Deloge E; Amour J; Provenchère S; Rozec B; Scherrer B; Ouattara A
Eur J Anaesthesiol; 2017 May; 34(5):280-287. PubMed ID: 28221207
[TBL] [Abstract][Full Text] [Related]
15. The effect of aprotinin, tranexamic acid, and aminocaproic acid on blood loss and use of blood products in major pediatric surgery: a meta-analysis.
Schouten ES; van de Pol AC; Schouten AN; Turner NM; Jansen NJ; Bollen CW
Pediatr Crit Care Med; 2009 Mar; 10(2):182-90. PubMed ID: 19188875
[TBL] [Abstract][Full Text] [Related]
16. The influence of aprotinin and tranexamic acid on platelet function and postoperative blood loss in cardiac surgery.
Mengistu AM; Röhm KD; Boldt J; Mayer J; Suttner SW; Piper SN
Anesth Analg; 2008 Aug; 107(2):391-7. PubMed ID: 18633013
[TBL] [Abstract][Full Text] [Related]
17. Coronary artery bypass grafting after aprotinin: are we doing better?
Beckerman Z; Shopen Y; Alon H; Cohen O; Nir RR; Adler Z; Bolotin G
J Thorac Cardiovasc Surg; 2013 Jan; 145(1):243-8. PubMed ID: 23072702
[TBL] [Abstract][Full Text] [Related]
18. A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting.
Levy JH; Pifarre R; Schaff HV; Horrow JC; Albus R; Spiess B; Rosengart TK; Murray J; Clark RE; Smith P
Circulation; 1995 Oct; 92(8):2236-44. PubMed ID: 7554207
[TBL] [Abstract][Full Text] [Related]
19. Comparison of blood-conservation strategies in cardiac surgery patients at high risk for bleeding.
Nuttall GA; Oliver WC; Ereth MH; Santrach PJ; Bryant SC; Orszulak TA; Schaff HV
Anesthesiology; 2000 Mar; 92(3):674-82. PubMed ID: 10719945
[TBL] [Abstract][Full Text] [Related]
20. Overview of clinical efficacy and safety of pharmacologic strategies for blood conservation.
Levy JH
Am J Health Syst Pharm; 2005 Sep; 62(18 Suppl 4):S15-9. PubMed ID: 16227191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
